Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours

Clinical trial NCT03697304 · COMPLETED

Trial details

NCT number: NCT03697304
Sponsor: Boehringer Ingelheim
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Neoplasm Metastasis Advanced Tumors Metastatic Solid Tumors

Start date: 2019-03-19
Primary completion: 2024-12-03
Enrollment: 211

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.